Turku UH

Varsinais-Suomen Sairaanhoitopiitin Kuntayhtyma, Turku, Finland

Group Description

Brief description of legal entity
Turku PET Centre (TPC) is a Finnish National Research Institute for the use of short-lived positron emitting isotopes in the field of medical research. The Centre was established in 1970s and it got National status in 1996. The core functions of Turku PET Centre are based on the agreement between University of Turku, Åbo Akademi University and Turku University Hospital. The Centre consists of Accelerator Laboratory, Radiopharmaceutical chemistry laboratory, Preclinical imaging laboratory and clinical PET imaging laboratory.

Main tasks
The four main research interest areas of TPC are 1) brain neurotransmission in health and disease, b) metabolism, c) preclinical imaging and drug development, d) radiochemistry research. The purpose of the clinical neurological project at TPC is to study normal ageing, cognitive brain functions and the aetiology and pathophysiology and treatment of neurodegenerative diseases. In normal human brain the effect of ageing on neurotransmitter systems and especially the role of brain dopaminergic system in memory and language functions in investigated. Of the neurodegenerative diseases main focus is on Parkinson´s disease and Alzheimer´s disease. In Alzheimer´s disease main research areas are ways to enable early diagnosis, development of new PET ligands for early detection, drug development and clinical follow-up and clinical drug trials including brain imaging as a possible surrogate marker of efficacy.

Participation in INMiND:  WP3 / WP6 / WP7 / WP8

Previous experience relevant to INMiND tasks

At TPC we have together with pharmaceutical industry developed new PET tracers to image TSPO. First studies in healthy volunteers and patients with Alzheimer´s disease (AD) have been conducted. Additional studies in patients with multiple sclerosis and animal models for MS and AD will be started in the near future. We also have used [11C]PK11195 both in patients with AD and MS. Other research line intimately relevant to INMiND tasks is our longstanding experience to synthesize and use (preclinical and human studies) of various amyloid imaging tracers including [11C]PIB and
[18F]flutemetamol.


University of Turku
Prof Juha RINNE
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: